Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Recruiting 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 175Neoplasm Metastasis 19Breast Neoplasms 19Prostatic Neoplasms, Castration-Resistant 17Neoplasms 16Metastatic Castration Resistant Prostate Cancer 8Prostate Cancer Metastatic 7Metastatic Castration-Resistant Prostate Cancer 7Triple Negative Breast Neoplasms 6Metastatic Castration-resistant Prostate Cancer 6Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Melanoma 4Colorectal Neoplasms 4Castration-resistant Prostate Cancer 4Bulbo-Spinal Atrophy, X-Linked 4Adenocarcinoma 4Urinary Bladder Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Prostate Adenocarcinoma 3Ovarian Neoplasms 3Carcinoma, Hepatocellular 3mCRPC 2Uterine Cervical Neoplasms 2Recurrence 2Prostatic Diseases 2Metastatic Hormone Sensitive Prostate Cancer 2Metastatic Castration-Resistant Prostate Cancer (mCRPC) 2

Interventions

Radiosurgery 4Magnetic Resonance Spectroscopy 4luprolide acetate gel depot 3enzalutamide 3Radiotherapy 3Radiation 3Leuprolide 3Goserelin 3relugolix 2gallium 68 PSMA-11 2bicalutamide 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Triptorelin Pamoate 2Specimen Handling 2Biopsy 2radium Ra 223 dichloride 1niraparib 1histrelin 1fluciclovine F-18 1flibanserin 1entinostat 1darolutamide 1atezolizumab 1apalutamide 1abiraterone 1X-Rays 1Watchful Waiting 1Salicylic Acid 1Receptors, Bombesin 1Radium-223 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Prostate Adenocarcinoma × enzalutamide × Clear all
NCT06257693 2026-02-27

Enzalutamide Implants (Enolen) in Patients With Prostate Cancer

Alessa Therapeutics Inc.

Phase 1 Recruiting
56 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT06499870 2025-10-21

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

NCT03829930 2021-08-02

Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

George Washington University

Phase 1 Terminated
6 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡